

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (Cancelled).

11. (Currently Amended) A composition for inhibiting endothelial cell proliferation comprising a Kunitz-3 domain fragment of a tissue factor pathway inhibitor, or an active fragment thereof, in and a pharmaceutically acceptable carrier.

12. (Currently Amended) The composition of Claim 11, ~~wherein the tissue factor pathway inhibitor comprises an active fragment of the Kunitz-3 domain of tissue factor pathway inhibitor,~~ wherein the active fragment inhibits cell proliferation.

13. (Cancelled).

14. (Currently Amended) The composition of Claim 12, wherein the active fragment inhibits angiogenesis.

15. (Currently Amended) The composition of Claim 12, wherein the active fragment inhibits angiogenesis-related disease.

16. (Currently Amended) The composition of Claim 15, wherein the ~~angiogenic-related~~ angiogenesis-related disease is a disease selected from the group consisting of cancer, arthritis, macular degeneration, and diabetic retinopathy.

17. (Currently Amended) The composition of Claim 12, wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in ~~SEQ ID NO. 1~~ SEQ ID NO:1.

18. (Withdrawn) The composition of Claim 12 wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in SEQ ID NO. 2.

19. (Cancelled).

20. (Previously Amended) The composition of Claim 11, wherein the carrier is a sustained-release matrix.